2 Biotech Stocks to Buy Hand Over Fist in December [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
It's hard to say, but many individual biotech stocks still look like solid long-term picks. That includes CRISPR Therapeutics (NASDAQ: CRSP) and Exelixis (NASDAQ: EXEL) . The former is well in the red for the year, while the latter has crushed the broader market this year. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects. Read on to learn more. Are You Missing The Morning Scoop? Breakfast News delivers it all in a quick, Foolish, and free daily newsletter. Sign Up For Free » CRISPR Therapeutics is a gene-editing specialist with a major claim to fame: It created Casgevy, the first approved medicine that uses the Nobel prize-winning CRISPR technique. The company developed this therapy with the help of Vertex Pharmaceuticals Casgevy's first approval came down in November 2023, but CRISPR Therapeutics' shares have underperformed the market since. What gives? First, Casgevy has yet to contribute a single dollar in sales to the bi
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $94.00 price target on the stock.MarketBeat
- CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual MeetingGlobeNewswire
- CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- 3 of the Best Growth Stocks You Can Buy for Less than $100 [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/5/24 - Beat
CRSP
Sec Filings
- 12/10/24 - Form SC
- 12/4/24 - Form 4
- 11/13/24 - Form 4
- CRSP's page on the SEC website